2014 News Releases

Webcast ImageWebcast
Clearside Biomedical Inc at the Deutsche Bank 42nd Annual Health Care Conference  (Live)
05/03/17 at 4:10 p.m. ET
Clearside Biomedical Inc at the Deutsche Bank 42nd Annual Health Care Conference
Wednesday, May 3, 2017 4:10 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
10/15/14Clearside Biomedical, Inc. Announces Ongoing Results in Phase 1/2 Clinical Trial in Patients with Non-infectious Uveitis
ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc. today announced the eight-week ongoing observations in patients with non-infectious uveitis. In the phase 1/2 clinical study, eight patients diagnosed with non-infectious uveitis at three U.S. study centers received a single suprachoroidal injection of a formulation of preservative-free triamcinolone acetonide injectable suspension using Clearside’s proprietary microinjector. Of the eight patient... 
Printer Friendly Version
09/04/14Clearside Biomedical, Inc. Announces Fourth Patent Allowance in the U.S. Related to Proprietary Microneedle Drug Delivery Methods and Devices
ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., announces the U.S. Patent and Trademark Office (USPTO) granted U.S. Patent Application No. 13/447,246 as U.S. Patent No. 8,808,225 in a patent titled, "Methods and Devices for Drug Delivery to Ocular Tissue Using Microneedle." This is the fourth patent allowance in the U.S. related to its proprietary microneedle drug delivery methods and devices. “Methods and Devices for Drug Delivery to Ocular ... 
Printer Friendly Version
09/02/14Clearside Biomedical, Inc. Completes $16 Million Series B Financing
ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., today announced the closing of a $16 million Series B financing. The financing included new investor RusnanoMedInvest (RMI) and existing investors Hatteras Venture Partners, Santen Pharmaceuticals Co. Ltd., Mountain Group Capital and Georgia Research Alliance Venture Fund. Clearside expects to use proceeds from this financing to fund continued development of Clearside’s proprietary suprachoroida... 
Printer Friendly Version
01/29/14Clearside Biomedical to Present Research on Proprietary Retinal Therapeutics Platform at 2014 ARVO Meeting
ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., announces the U.S. Patent and Trademark Office (USPTO) granted U.S. Patent Application No. 13/453,407 as U.S. Patent No. 8,636,713 in a patent titled, "Methods and Devices for Drug Delivery to Ocular Tissue Using Microneedle." This is the third patent allowance in the U.S. related to its proprietary microneedle drug delivery methods and devices. “Methods and Devices for Drug Delivery to Ocular T... 
Printer Friendly Version
01/29/14Clearside Biomedical, Inc. Announces Third Patent Allowance in the U.S. Related to Proprietary Microneedle Drug Delivery Methods and Devices
ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., announces the U.S. Patent and Trademark Office (USPTO) granted U.S. Patent Application No. 13/453,407 as U.S. Patent No. 8,636,713 in a patent titled, "Methods and Devices for Drug Delivery to Ocular Tissue Using Microneedle." This is the third patent allowance in the U.S. related to its proprietary microneedle drug delivery methods and devices. “Methods and Devices for Drug Delivery to Ocular T... 
Printer Friendly Version